There is evidence from neuroblastoma cell line studies that MYCN amplified neuroblastoma cells may circumvent MYCN driven p53-dependent apoptosis by selecting for cells with aberrations in the p53/MDM2/p14ARF pathway. The gene discussed is MDM2; the disease is neuroblastoma.